Jin and Juice Investments

Who knew investing could be so much fun =D

Posts Tagged ‘xoma sec filing

XOMA’s Strategic Agenda – Words from CEO Mr. Engle

with 4 comments



Recently, the Wall Street Transript released their Biotechnology report which provides a unique and informative insight into the future of a select few public companies.  Below is a brief interview with the CEO of XOMA, Mr. Steve Engle on the current events taking place at XOMA and his strategic agenda for the next few years.

“TWST Question: Please begin with a brief historical sketch of the company and a picture of the things you are doing at the present time.

Mr. Engle CEO of XOMA Response: We are a recognized leader in the discovery and development of therapeutic antibodies. Our lead product, XOMA 052, is a potentially revolutionary treatment for the inflammatory cause of many major diseases including Type II diabetes, cardiovascular disease and autoimmune diseases. In addition, XOMA receives revenues from: the licensing of its antibody technologies to over 50 companies; product royalties (LUCENTIS and CIMZIA); development collaborations with Takeda, Novartis and Schering-Plough; and biodefense contracts. Based in Berkeley, California, XOMA has 200 employees.Our lead product candidate, XOMA 052, is a proprietary antibody that regulates production of the cytokine called interleukin-1 or IL-1, which is the master cytokine in activating the inflammatory cascade. We recently received a US patent for XOMA 052, providing an important acknowledgement that it has properties that differentiate it from other agents that target IL-1. We recently completed enrollment in Phase I studies of XOMA 052 in Type II diabetes and plan to announce top-line results from the US trial in July. The trials evaluated a wide range of XOMA 052 doses, single and multiple dose regimens, and intravenous and subcutaneous routes of administration. Interim results presented last fall from the single dose IV trials demonstrated that XOMA 052 is well tolerated across all doses. Further, XOMA 052 showed evidence of biological activity, including reduced levels of glycosylated hemoglobin, increased insulin production and reduced levels of C-reactive protein, or CRP, compared to placebo. CRP is a well-established marker for the systemic inflammation associated with cardiovascular disease, one of the largest pharmaceutical markets. For this reason, we have begun to evaluate XOMA 052 for its potential cardiovascular benefits in addition to considering it for development in diabetes and autoimmune diseases. In addition to XOMA 052 and the other products in our proprietary pipeline, we have a business focused on collaborations with other companies using our broad antibody technologies, a business focused on biodefense funded by the US government, and a royalty-based business based on our pioneering position in developing antibodies for therapeutic uses. We currently receive royalties on sales of LUCENTIS from Genentech and CIMZIA from UCB.

TWST Question: Would you sketch out your strategic agenda for the next two to three years?

Mr. Engle CEO of XOMA Response: We are very focused on advancing the development of XOMA 052 for diabetes and cardiovascular disease because it is a revolutionary approach and has the greatest single potential for maximizing the return to shareholders. Discussions toward a corporate partnership for XOMA 052 are underway and we plan to finalize this partnership by year-end. We plan to advance XOMA 052 for other indications and continue bringing forward the other proprietary compounds we have in pre-clinical development. With the advancement of XOMA 052, establishment of a corporate partnership, advancement of our pre-clinical pipeline and our other businesses, we believe we have multiple opportunities to significantly grow shareholder value.”


Therapeutic Antibodies Potential to Revolutionalize Treatment of Autoimmune Diseases

�Analysts Recommendations

current 1 Month Ago 3 Months Ago
BUY 3 5 5
HOLD 1 0 0
SELL 0 0 0

Mean Recomendation Conversion Table
1.00 thru 1.24 = Buy
1.25 thru 1.74 = Overweight
1.75 thru 2.24 = Hold
2.25 thru 2.74 = Underweight
2.75 thru 3.00 = Sell
Copyright © 2006 FactSet JCF S.A.S. All rights reserved.



Written by jinandjuice2009

June 1, 2009 at 1:56 PM

A Few Things To Remember – XOMA

with 9 comments

Recent Highlights and Developments

 * Completed enrollment in XOMA 052 Phase 1 program in Type 2
   diabetes: Nearly 100 Type 2 diabetes patients were enrolled
   in the Phase 1 trials, which were designed to evaluate a wide
   range of dose levels, single and multiple dose regimens, and
   intravenous and subcutaneous routes of administration. Interim
   results from the single dose intravenous trials, presented in
   September 2008, demonstrated that XOMA 052 was well-tolerated
   across all doses and demonstrated biological activity, including
   reduced levels of glycosylated hemoglobin, increased insulin
   production and decreased levels of C-reactive protein (CRP), a
   marker of cardiovascular risk. These interim results support the
   potential for XOMA 052 as a novel anti-inflammatory approach to
   diabetes treatment and XOMA's plan to initiate a Phase 2 program
   in the third quarter of 2009.

 * Expanded Takeda collaboration, which provided XOMA with a $29
   million fee and potential future milestones and royalties: In
   February 2009, Takeda Pharmaceutical Company Limited (Takeda) and
   XOMA expanded an existing collaboration to provide Takeda with
   access to multiple antibody technologies, including a suite of
   integrated information and data management systems.  XOMA has
   paid $5.8 million of an estimated $7.5 million for taxes and
   other costs related to the expanded collaboration, resulting in
   net cash proceeds received in February 2009 of $23.2 million.

 * Reduced operating costs: XOMA has undertaken multiple cost
   reduction measures that have allowed the company to focus
   research and development spending on the most promising
   proprietary development programs, including XOMA 052 in Type 2
   diabetes. The company expects an annualized reduction of $27
   million in cash expenditures when reductions are completed in
   the current quarter.

Written by jinandjuice2009

May 25, 2009 at 4:00 PM

XOMA – Feeling like a Bag Holder!?

leave a comment »

XOMA – Feeling like a Bag Holder?

If you bought XOMA high and are pissed off since the price has dropped considerably.  Think about this before you sell and realize huge losses.  Why do big orders keep driving the price up and then small orders for 100 shares keep driving the price down?  This is known as manipulation.  Set to drive prices down that trigger stop losses.

You can follow the trend here on nasdaq:  XOMA Real Time quotes

Also Take a look at the Major Insider Holdings: XOMA Insider Activity

This is a great opportunity to practice patience.   In the the meanwhile go rent:  Boiler Room

Check out:

Written by jinandjuice2009

May 22, 2009 at 12:32 AM

Posted in XOMA

Tagged with